Contains Nonbinding Recommendations

Draft Guidance on Hydroxyurea

This draft guidance, once finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

Active ingredient: Hydroxyurea

Form/Route: Capsules /Oral

Recommended studies: 2 study

Type of study: Fasting
Design: Single-dose, two-way, crossover *in-vivo*
Strength: 500 mg
Subjects: Adult male and female who are on stable regimens of hydroxyurea for the treatment of Sickle Cell Anemia.
Additional Comments: Submission of an Investigational New Drug Application (IND) is required prior to the conduct of a bioequivalence study for a cytotoxic drug product (See 21 C.F.R § 320.31).

Analytes to measure (in appropriate biological fluid): Hydroxyurea in plasma

Bioequivalence based on (90% CI): Hydroxyurea

Waiver request of in-vivo testing: 200 mg, 250 mg, 300 mg, and 400 mg based on (i) acceptable bioequivalence studies on the 500 mg strength, (ii) acceptable dissolution testing across all strengths, and (iii) proportional similarity in the formulations across all strengths.

Dissolution test method and sampling times:

Please note that a **Dissolution Methods Database** is available to the public at the OGD website at http://www.fda.gov/cder/ogd/index.htm. Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the application.